Continuous Data Collection
Bring everyday and treatment records together
Understand patients through Dr.SAM conversations, DTx treatment records and health information.
DrugOS™ · AI-Augmented TherapeuticsDeeper patient understanding
Deeper patient understanding
More precise treatment
Understand patients through their habits, symptoms and treatment responses.
Build precision therapies and new treatment technologies on that understanding.
Official introduction · English · 5:20
DrugOS™AI Agent
Patient Data
Clinician
Everyday life is part of treatment
Life and symptoms change between consultations.
DrugOS™ develops technology to understand those changes and inform treatment.
Daily habits
Patterns of sleep and activity
Symptom changes
Symptoms over time
Treatment responses
Changes during treatment
DrugOS™
From Data to Decision: The DrugOS™ System
A cycle of patient understanding and treatment development
01Patient DataDr.SAM · DTx
Health information
Health information
02Patient understandingDaily habits · Symptoms
Treatment responses
Treatment responses
DrugOS™
03Treatment developmentDTx
Digital combination drugs
Digital combination drugs
04Records & responsesInform development
and validation
and validation
Personalized Intelligence
Understand individual patterns and responses
Analyze daily habits, symptom changes and treatment responses together.
Treatment development
Turn patient understanding into treatment technology
Develop precision therapies and extend applications to DTx and digital combination drugs.
Evidence feedback
Bring treatment records back into development
Use accumulated treatment records and responses to deepen patient understanding.
Applying patient understanding to treatment
Condition-specific treatment programs
Treatment records inform condition-specific programs.
SleepQ® · MFDS authorized · Commercial
SerenQ® · MFDS authorized
Interpretable Decision Support
Developing technology to follow symptoms and medication responses and organize treatment progress.
In development
Explore digital combination drugsDevelopment and evaluation
Follow-on pipeline development time
54%
shorter
27 months→12.5 months
SleepQ® SerenQ®
Dr.SAM medical-dialogue evaluation
65.8%
reduction in evaluation error rate
Before 4.50%→After 1.54%
Same AI model · Internal evaluation, September 2026
How we evaluated Dr.SAM
The evaluation tested whether AI accepted fabricated conditions or misleading medical information as fact. Adding Dr.SAM to the same AI reduced the share of assessment items that failed the criteria from 4.50% to 1.54%.
- Evaluation set
- MHB-Dialogue · 2,602 dialogues and 11,623 assessment items
- Comparison
- The same AI model (GPT-5.6) and basic execution conditions were compared with and without Dr.SAM’s instructions and operating layer.
- Date and evaluator
- September 2026 internal company evaluation
65.8% is the relative reduction from 4.50% to 1.54% in this medical-dialogue evaluation. It is not a real-world clinical error rate, diagnostic accuracy measure or clinical efficacy result.